Allarity Therapeutics
Yahoo Finance • 16 days ago
Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission
Boston (March 13, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—today ann... Full story
Yahoo Finance • 23 days ago
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration
Trial to explore novel combination therapy for patients with recurrent Small Cell Lung Cancer who have failed frontline treatment Fully funded by the U.S. Veterans’ Administration Special Emphasis Panel on Precision Oncology Trial builds o... Full story
Yahoo Finance • last month
Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit
Boston (February 26, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a p... Full story
Yahoo Finance • last month
Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients
Patient enrollment set to begin at leading U.S. clinical trial sites, new drug product already delivered Trial will advance stenoparib and the stenoparib-DRP Companion Diagnostic toward FDA approval Two patients in the ongoing phase 2 tria... Full story
Yahoo Finance • 2 months ago
Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer
Boston (February 6, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a pe... Full story
Yahoo Finance • 2 months ago
Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC
Boston (January 30, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments using its proprietary, drug-specific... Full story
Yahoo Finance • last year
Allarity Therapeutics to Present at Biomarkers Europe 2023
Allarity will present on development of several drug-specific DRP® companiondiagnostics, and participate in a panel discussion with speakers from Merck and Roche BOSTON, October 2, 2023 — Allarity Therapeutics, Inc. (Allarity or the Compa... Full story
Yahoo Finance • 2 years ago
PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib
- The DRP®-Dovitinib companion diagnostic demonstrated an ability to identify advanced renal cell carcinoma patients that have improved clinical benefit from dovitinib treatment, as compared to unselected patients BOSTON (August 30, 2023)... Full story
Yahoo Finance • 2 years ago
Allarity Therapeutics, Inc. Announces Pricing of $11 Million Public Offering
BOSTON, MA (July 6, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for... Full story
Yahoo Finance • 2 years ago
Initial Data from Allarity’s Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients
Boston, MA (July 5, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (Nasdaq: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for... Full story
Yahoo Finance • 2 years ago
Allarity Therapeutics Announces Reverse Stock Split of Common Stock
- Common Stock Will Begin Trading on a Post-Split Adjusted Basis on June 29, 2023 Press Release BOSTON, MA (June 28, 2023) – Allarity Therapeutics, Inc. (NASDAQ: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical comp... Full story
Yahoo Finance • 2 years ago
Allarity Therapeutics Announces Clarification of Effective Date for Reverse Stock Split
Press Release BOSTON, MA (June 27, 2023) – Allarity Therapeutics, Inc. (NASDAQ: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion... Full story
Yahoo Finance • 2 years ago
Allarity Therapeutics Announces Adjournment of Special Meeting of Stockholders
Meeting adjourned to Friday, June 23, 2023 at 1:00 p.m. Eastern Time Press release BOSTON, MA (June 20, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing... Full story
Yahoo Finance • 2 years ago
Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering
Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering BOSTON, MA (April 19, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel... Full story
Yahoo Finance • 2 years ago
Abstract Evaluating Allarity’s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting
FOR IMMEDIATE RELEASE Abstract Evaluating Allarity’s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting Poster presentation focused on a Phase 2 Clinical Study Evaluating the Utility of a DRP® Companion Diagnost... Full story
Yahoo Finance • 2 years ago
Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies
Efforts underway to accelerate patient recruitment and amend protocols to improve patient outcomes. Interim data readouts for both studies anticipatedinH2 2023. Press release BOSTON — March 28, 2023– Allarity Therapeutics, Inc. (NASDAQ... Full story
Yahoo Finance • 2 years ago
Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors
Company anticipates that the combination of pan-TKI dovitinib and PARP inhibitor stenoparib maygenerate synergistic anti-cancer activity Program initiation marks key milestone in Allarity’s clinical strategy shift towards combination the... Full story
Yahoo Finance • 2 years ago
Allarity Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
Press release Boston, MA U.S.A. (January 20, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diag... Full story
Yahoo Finance • 2 years ago
Allarity Therapeutics Reschedules 2022 Annual Stockholders Meeting and Sets New Record Date
PRESS RELEASE Boston, MA U.S.A. (December 1, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diag... Full story
Yahoo Finance • 2 years ago
Allarity Therapeutics Reports Third Quarter 2022 Financial Results
Press release Cambridge, MA U.S.A. (November 15, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion... Full story
